Hospital
Dana-Farber Cancer Institute, INC.
Dana-Farber Cancer Institute, INC. was paid $240.21M by Medicaid between Jan 2018 and Dec 2024, across 357 billing codes. Its largest line is J9271, Injection, pembrolizumab, 1 mg — 14% of everything it billed.
33Billing provider infoDANA-FARBER CANCER INSTITUTE, INC.
BOSTON, MA 02215
BOSTON, MA 02215
33aNPI1851333686assigned 06/13/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$240.21M
24GClaims2,372,309
24DCodes billed357
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#7 of 66
Median peer was paid$29.11M
This provider vs. median8.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 258,114 | $18.88M | |
| 2019 | 276,052 | $22.13M | |
| 2020 | 296,963 | $26.34M | |
| 2021 | 391,024 | $36.11M | |
| 2022 | 393,533 | $40.08M | |
| 2023 | 395,686 | $49.80M | |
| 2024incomplete | 360,937 | $46.86M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 14% | 6,182 | 4,491 | $33.02M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 11% | 123,385 | 80,896 | $25.44M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 5.5% | 75,242 | 41,464 | $13.14M |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 4.6% | 5,051 | 3,462 | $11.11M |
| J9299 | Injection, nivolumab, 1 mg | 4.5% | 2,754 | 1,817 | $10.92M |
| J9035 | Injection, bevacizumab, 10 mg | 3.7% | 6,685 | 2,750 | $8.80M |
| J2505 | Injection, pegfilgrastim, 6 mg | 3.6% | 3,900 | 2,804 | $8.66M |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.0% | 21,276 | 13,046 | $7.13M |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | 2.1% | 3,381 | 2,351 | $5.06M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.9% | 149,281 | 102,728 | $4.62M |
| 96415 | 1.8% | 14,913 | 9,021 | $4.43M | |
| J9306 | Injection, pertuzumab, 1 mg | 1.8% | 1,706 | 1,207 | $4.30M |
345 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 50,625 | $4.05M |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 1.7% | 1,656 | $4.04M |
| 80053 | Comprehensive metabolic panel | 1.7% | 190,810 | $4.00M |
| 36430 | 1.5% | 10,799 | $3.69M | |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.4% | 3,602 | $3.44M |
| J9358 | Injection, fam-trastuzumab deruxtecan-nxki, 1 mg | 1.4% | 1,252 | $3.43M |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.3% | 22,267 | $3.17M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 19,265 | $3.00M |
| J2796 | Injection, romiplostim, 10 micrograms | 1.2% | 3,634 | $2.91M |
| J0185 | Injection, aprepitant, 1 mg | 1.2% | 12,866 | $2.79M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 11,796 | $2.58M |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 4,772 | $2.30M |
| J9041 | Injection, bortezomib, 0.1 mg | <1% | 5,655 | $2.19M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 27,641 | $2.18M |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 9,620 | $2.17M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 12,847 | $1.95M |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 11,466 | $1.83M |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | <1% | 3,086 | $1.80M |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 19,705 | $1.76M |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 5,500 | $1.70M |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 13,698 | $1.67M |
| J0897 | Injection, denosumab, 1 mg | <1% | 2,559 | $1.55M |
| 96367 | <1% | 14,148 | $1.54M | |
| 96401 | <1% | 9,809 | $1.50M | |
| J1950 | Injection, leuprolide acetate (for depot suspension), per 3.75 mg | <1% | 1,279 | $1.46M |
| J9395 | Injection, fulvestrant, 25 mg | <1% | 2,254 | $1.41M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 3,501 | $1.41M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 197,766 | $1.39M |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 9,953 | $1.33M |
| J9305 | Injection, pemetrexed, not otherwise specified, 10 mg | <1% | 783 | $1.23M |
| 96409 | <1% | 13,502 | $1.16M | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,888 | $1.15M |
| 77386 | <1% | 4,867 | $1.05M | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 5,806 | $1.03M |
| 96416 | <1% | 4,829 | $987K | |
| 96411 | <1% | 16,429 | $985K | |
| 99205 | Prolong outpt/office vis | <1% | 3,938 | $954K |
| 77412 | <1% | 3,682 | $950K | |
| J9312 | Injection, rituximab, 10 mg | <1% | 560 | $852K |
| 96417 | <1% | 19,594 | $851K | |
| 80050 | General health panel | <1% | 11,294 | $830K |
| 38222 | <1% | 2,107 | $741K | |
| 88185 | <1% | 3,805 | $738K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 17,081 | $710K |
| J9070 | Cyclophosphamide, 100 mg | <1% | 3,028 | $652K |
| 83735 | <1% | 82,349 | $630K | |
| J2353 | Injection, octreotide, depot form for intramuscular injection, 1 mg | <1% | 252 | $563K |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | <1% | 242 | $537K |
| Q2050 | Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg | <1% | 294 | $512K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 11,329 | $508K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 1,498 | $485K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 8,026 | $482K |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | <1% | 4,195 | $481K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 2,280 | $464K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 2,641 | $460K |
| 96402 | <1% | 10,255 | $451K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 7,460 | $443K |
| 96368 | <1% | 9,396 | $430K | |
| 82378 | <1% | 25,047 | $427K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 7,652 | $411K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,860 | $337K |
| 77336 | <1% | 3,740 | $335K | |
| 86850 | <1% | 28,659 | $315K | |
| J9354 | Injection, ado-trastuzumab emtansine, 1 mg | <1% | 181 | $310K |
| J3490 | Unclassified drugs | <1% | 15,622 | $289K |
| J1750 | Injection, iron dextran, 50 mg | <1% | 1,968 | $287K |
| ATP14 | <1% | 35,891 | $282K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 14,183 | $278K |
| 82784 | <1% | 20,154 | $273K | |
| 96450 | <1% | 397 | $267K | |
| 82728 | <1% | 27,350 | $258K | |
| J9316 | Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg | <1% | 34 | $250K |
| 31575 | <1% | 1,322 | $238K | |
| P9037 | Platelets, pheresis, leukocytes reduced, irradiated, each unit | <1% | 1,067 | $236K |
| 87497 | <1% | 6,352 | $231K | |
| J9022 | Injection, atezolizumab, 10 mg | <1% | 36 | $229K |
| J9206 | Injection, irinotecan, 20 mg | <1% | 5,148 | $227K |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 1,967 | $210K |
| 86923 | <1% | 6,783 | $204K | |
| 86300 | <1% | 9,877 | $194K | |
| 86900 | <1% | 29,436 | $193K | |
| 99443 | <1% | 1,510 | $191K | |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | <1% | 61 | $188K |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 10,852 | $186K |
| 86901 | <1% | 28,897 | $186K | |
| 74183 | <1% | 818 | $185K | |
| 78816 | <1% | 258 | $167K | |
| 84100 | <1% | 46,585 | $156K | |
| 86304 | <1% | 9,166 | $155K | |
| 87799 | <1% | 2,424 | $154K | |
| 83615 | <1% | 42,578 | $153K | |
| J9310 | Injection, rituximab, 100 mg | <1% | 142 | $150K |
| 85027 | <1% | 22,468 | $147K | |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion | <1% | 2,892 | $143K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,368 | $136K |
| 86334 | <1% | 11,808 | $136K | |
| 96377 | <1% | 4,677 | $134K | |
| 88184 | <1% | 3,824 | $134K | |
| 84439 | <1% | 12,324 | $130K | |
| 83550 | <1% | 19,150 | $128K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,974 | $127K |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | <1% | 184 | $123K |
| 97803 | <1% | 1,307 | $118K | |
| 76642 | <1% | 1,326 | $107K | |
| 83540 | <1% | 22,539 | $107K | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 4,908 | $104K |
| 80076 | <1% | 5,442 | $103K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 6,442 | $100K |
| 78306 | <1% | 608 | $100K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 383 | $91K |
| ATP15 | <1% | 11,765 | $91K | |
| 86301 | <1% | 5,804 | $91K | |
| 82248 | <1% | 22,530 | $89K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 3,575 | $89K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,887 | $88K |
| 82607 | <1% | 8,676 | $80K | |
| 83521 | <1% | 6,249 | $77K | |
| 83520 | <1% | 11,100 | $75K | |
| 81162 | <1% | 56 | $74K | |
| Q5115 | Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | <1% | 27 | $73K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12,680 | $70K |
| 85007 | <1% | 18,756 | $70K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,005 | $68K |
| 71250 | <1% | 1,440 | $65K | |
| 84702 | <1% | 3,419 | $62K | |
| 88237 | <1% | 1,025 | $61K | |
| 84153 | <1% | 8,323 | $61K | |
| 84165 | <1% | 12,747 | $60K | |
| 88342 | <1% | 1,547 | $59K | |
| J9171 | Injection, docetaxel, 1 mg | <1% | 497 | $54K |
| 84403 | <1% | 5,417 | $54K | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 8,714 | $51K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 18,200 | $48K |
| 70491 | <1% | 384 | $48K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 6,334 | $44K |
| 88108 | <1% | 507 | $42K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 15,353 | $40K |
| 88313 | <1% | 2,050 | $37K | |
| 80197 | <1% | 3,989 | $37K | |
| 85610 | <1% | 8,068 | $36K | |
| 72197 | <1% | 104 | $36K | |
| 81001 | <1% | 10,020 | $35K | |
| 86803 | <1% | 2,162 | $34K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,439 | $34K |
| 82746 | <1% | 3,923 | $34K | |
| J9173 | Injection, durvalumab, 10 mg | <1% | 34 | $33K |
| 88341 | <1% | 250 | $33K | |
| ATP16 | <1% | 4,609 | $32K | |
| 86141 | <1% | 3,229 | $32K | |
| 82150 | <1% | 4,215 | $31K | |
| 88262 | <1% | 233 | $31K | |
| 80061 | Lipid panel | <1% | 3,577 | $30K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,252 | $29K |
| J9145 | Injection, daratumumab, 10 mg | <1% | 74 | $29K |
| 85045 | <1% | 9,867 | $29K | |
| 77049 | <1% | 38 | $29K | |
| 96376 | <1% | 4,444 | $28K | |
| 84550 | <1% | 11,397 | $28K | |
| 86360 | <1% | 887 | $28K | |
| 86704 | <1% | 2,005 | $27K | |
| 82232 | <1% | 3,384 | $27K | |
| 36593 | <1% | 649 | $27K | |
| 87340 | <1% | 2,425 | $27K | |
| 82105 | <1% | 2,171 | $26K | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 5,792 | $25K |
| 90686 | <1% | 1,536 | $25K | |
| 85730 | <1% | 5,341 | $24K | |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg | <1% | 3,021 | $24K |
| 82565 | <1% | 6,022 | $24K | |
| 83690 | <1% | 3,300 | $22K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 30,171 | $22K |
| 88311 | <1% | 1,559 | $22K | |
| 82247 | <1% | 5,724 | $22K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 122 | $22K |
| 99195 | <1% | 744 | $21K | |
| 97802 | <1% | 379 | $21K | |
| J1190 | Injection, dexrazoxane hydrochloride, per 250 mg | <1% | 20 | $21K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,680 | $19K |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 3,239 | $19K |
| 81206 | <1% | 225 | $19K | |
| 89051 | <1% | 1,055 | $19K | |
| ATP17 | <1% | 2,844 | $19K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 10,233 | $18K |
| 84450 | <1% | 4,440 | $18K | |
| 77387 | <1% | 668 | $17K | |
| J9999 | Not otherwise classified, antineoplastic drugs | <1% | 156 | $17K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 11,971 | $17K |
| 81003 | <1% | 3,475 | $17K | |
| 86355 | <1% | 651 | $16K | |
| J9075 | Injection, cyclophosphamide, not otherwise specified, 5 mg | <1% | 148 | $16K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 18 | $15K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 9,955 | $15K |
| 0002A | <1% | 766 | $15K | |
| 86706 | <1% | 1,958 | $15K | |
| 77062 | <1% | 138 | $14K | |
| 77066 | Tomosynthesis, mammo | <1% | 770 | $14K |
| 86357 | <1% | 601 | $14K | |
| 85055 | <1% | 495 | $14K | |
| 77065 | Tomosynthesis, mammo | <1% | 428 | $13K |
| 99442 | <1% | 166 | $12K | |
| 0001A | <1% | 780 | $12K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,203 | $12K |
| 84520 | <1% | 3,167 | $11K | |
| J9060 | Injection, cisplatin, powder or solution, 10 mg | <1% | 2,177 | $10K |
| 81450 | <1% | 60 | $10K | |
| 87449 | <1% | 737 | $10K | |
| 86140 | <1% | 1,407 | $9K | |
| 77061 | <1% | 100 | $9K | |
| 80051 | <1% | 529 | $8K | |
| J9250 | Methotrexate sodium, 5 mg | <1% | 3,144 | $8K |
| ATP03 | <1% | 2,978 | $8K | |
| 85652 | <1% | 3,072 | $8K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 5,475 | $8K |
| 84466 | <1% | 1,834 | $8K | |
| 82670 | <1% | 349 | $8K | |
| 87305 | <1% | 624 | $8K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,613 | $7K |
| 82533 | <1% | 403 | $7K | |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 4,342 | $7K |
| ATP09 | <1% | 1,116 | $7K | |
| 82550 | <1% | 1,685 | $7K | |
| 84156 | <1% | 3,151 | $6K | |
| 96523 | <1% | 157 | $6K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 71 | $6K |
| 82570 | <1% | 2,386 | $6K | |
| J9071 | Injection, cyclophosphamide (auromedics), 5 mg | <1% | 102 | $6K |
| 82947 | <1% | 1,012 | $5K | |
| 81265 | <1% | 46 | $5K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 96 | $5K |
| 86335 | <1% | 914 | $5K | |
| 83001 | <1% | 309 | $5K | |
| 83010 | <1% | 900 | $5K | |
| J9181 | Injection, etoposide, 10 mg | <1% | 1,063 | $5K |
| 94010 | <1% | 219 | $5K | |
| 86356 | <1% | 112 | $5K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 8,640 | $4K |
| 36591 | <1% | 460 | $4K | |
| 94726 | <1% | 134 | $4K | |
| 86769 | <1% | 246 | $4K | |
| 83789 | <1% | 252 | $4K | |
| ATP02 | <1% | 1,237 | $4K | |
| 85044 | <1% | 1,295 | $4K | |
| G0008 | Administration of influenza virus vaccine | <1% | 995 | $4K |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 1,203 | $3K |
| 94729 | <1% | 135 | $3K | |
| 81267 | <1% | 78 | $3K | |
| 84166 | <1% | 1,092 | $3K | |
| J9260 | Injection, methotrexate sodium, 50 mg | <1% | 525 | $3K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 12 | $3K |
| 86644 | <1% | 134 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 916 | $3K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 162 | $3K |
| 87040 | <1% | 254 | $3K | |
| 81025 | <1% | 344 | $3K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 161 | $2K |
| 0003A | <1% | 144 | $2K | |
| 96040 | <1% | 26 | $2K | |
| 90662 | <1% | 364 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 781 | $2K |
| ATP18 | <1% | 300 | $2K | |
| 88381 | <1% | 39 | $2K | |
| 85097 | <1% | 96 | $2K | |
| 86316 | <1% | 223 | $2K | |
| 77300 | <1% | 12 | $2K | |
| 86665 | <1% | 65 | $2K | |
| J9100 | Injection, cytarabine, 100 mg | <1% | 262 | $2K |
| 90677 | <1% | 13 | $2K | |
| ATP08 | <1% | 284 | $2K | |
| 82668 | <1% | 302 | $2K | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 25 | $2K |
| 0004A | <1% | 105 | $2K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 52 | $1K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 5,079 | $1K |
| 36592 | <1% | 160 | $1K | |
| 99417 | Prolong home eval add 15m | <1% | 31 | $1K |
| 82610 | <1% | 159 | $1K | |
| 87081 | <1% | 518 | $1K | |
| 72158 | <1% | 12 | $1K | |
| 81268 | <1% | 46 | $1K | |
| 88360 | <1% | 39 | $1K | |
| 86922 | <1% | 205 | $1K | |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring | <1% | 16 | $1K |
| 87631 | <1% | 35 | $1K | |
| 86945 | <1% | 44 | $1K | |
| 86777 | <1% | 53 | $995.93 | |
| 84481 | <1% | 134 | $918.32 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,002 | $870.79 |
| 84155 | <1% | 1,259 | $858.25 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 29 | $825.00 |
| Q3014 | Telehealth originating site facility fee | <1% | 1,577 | $816.74 |
| 83516 | <1% | 112 | $777.63 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 823 | $772.81 |
| 90656 | <1% | 49 | $717.46 | |
| 86359 | <1% | 56 | $711.26 | |
| ATP07 | <1% | 133 | $710.64 | |
| Q0164 | Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,648 | $676.27 |
| 84478 | <1% | 250 | $653.96 | |
| 84460 | <1% | 145 | $628.85 | |
| 88271 | <1% | 88 | $613.55 | |
| 86787 | <1% | 40 | $604.61 | |
| 82043 | <1% | 198 | $569.13 | |
| 88275 | <1% | 21 | $538.46 | |
| 93000 | <1% | 13 | $532.81 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 185 | $485.08 |
| 84484 | <1% | 31 | $413.42 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 622 | $412.83 |
| 87077 | <1% | 78 | $380.46 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 17 | $380.40 |
| 85384 | <1% | 78 | $361.78 | |
| 86039 | <1% | 41 | $319.32 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 247 | $289.75 |
| 86902 | <1% | 32 | $276.01 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 29 | $275.00 |
| 87186 | <1% | 13 | $257.11 | |
| 83021 | <1% | 24 | $223.02 | |
| 90670 | <1% | 19 | $213.35 | |
| 83883 | <1% | 32 | $205.20 | |
| 86664 | <1% | 13 | $202.41 | |
| 88365 | <1% | 15 | $143.21 | |
| 83880 | <1% | 20 | $138.48 | |
| 84480 | <1% | 27 | $137.75 | |
| 82310 | <1% | 183 | $136.37 | |
| 0077U | <1% | 463 | $116.94 | |
| 83970 | <1% | 24 | $109.23 | |
| 86431 | <1% | 12 | $75.50 | |
| 83020 | <1% | 17 | $68.10 | |
| 82977 | <1% | 204 | $62.70 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 19 | $58.55 |
| 85049 | <1% | 37 | $44.99 | |
| 82465 | <1% | 42 | $44.88 | |
| 91300 | <1% | 688 | $40.50 | |
| 82374 | <1% | 45 | $25.14 | |
| 84132 | <1% | 52 | $24.39 | |
| 85018 | <1% | 37 | $23.76 | |
| 85014 | <1% | 36 | $21.60 | |
| 85651 | <1% | 16 | $18.25 | |
| ATP13 | <1% | 15 | $10.89 | |
| 85041 | <1% | 13 | $8.28 | |
| 84295 | 0% | 17 | $0.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 78 | $0.00 |
| Q0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg | 0% | 16 | $0.00 |
| 77417 | 0% | 76 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 36 | $0.00 |
| G0009 | Administration of pneumococcal vaccine | 0% | 12 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEMBINSKI, PAUL (SR. DIRECTOR OF PFS)
| Provider | Location | Paid |
|---|---|---|
| Dana-Farber Cancer Institute, INC. | Boston, MA | $4.81M |
| Dana-Farber Cancer Institute, INC. | Boston, MA | $24K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.